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What is the best way to identify
patients with white-coat hypertension?
E V I D E N C E - B A S E D A N S W E R
Ambulatory BP monitoring better than home
monitoring for ruling out white-coat hypertension
Landmark placebo-controlled outcome-based trials
demonstrating reduced morbidity and mortality
with hypertension treatment did not differentiate
essential from white-coat hypertension. Patients
were included based on elevated office-based
blood pressure measurements. Since we now
know that the prevalence of white-coat hyper-
tension is high, it should be ruled out before
implementing antihypertensive therapy. 
Ambulatory blood pressure monitoring is
more accurate than home monitoring for ruling
out white-coat hypertension. However, ease, 
simplicity, and availability makes home monitoring
a more realistic option for routine clinical practice.
When home blood pressure monitoring is used,
reliable measurement devices (eg, newer 
automatic or manual home devices) should 
be used and patients should be instructed 
regarding proper use and documentation of 
blood pressure values to facilitate an appropriate
clinical assessment.
Joseph Saseen, PharmD, FCCP, BCPS
University of Colorado Health Sciences Center, Denver
Ambulatory blood pressure monitoring is current-
ly the gold standard for detecting patients with
white-coat hypertension. Women and all patients
with lower office systolic blood pressures, stage 
I hypertension, and no target organ damage are
more likely to have white-coat hypertension
(strength of recommendation [SOR]: B, based on
prospective cohort studies) (TABLE). 
Self or home blood pressure monitoring has
also been used to detect patients with white-coat
hypertension. However, it has a low sensitivity
(61%–68%) and low positive predictive value
(PV+) (33%–48%) (SOR: B, short-term prospective
cohort studies).
C L I N I C A L C O M M E N T A R Y
■ Evidence summary
White coat hypertension, also known as
isolated office hypertension, refers to ele-
vated blood pressures in a medical setting
and normal blood pressures during regular
daily life. Patients with white-coat hyper-
tension are defined as patients 1) with an
office blood pressure of >140 mm Hg sys-
tolic or >90 mm Hg diastolic on at least 3
separate office visits with 2 measurements
each visit and 2) mean daytime blood pres-
sure of <135 mm Hg systolic and <85 mm
Hg diastolic on ambulatory blood pressure
monitoring.1 Other measures of normal
blood pressure on ambulatory blood pres-
sure monitoring are <130/80 mm Hg for
full 24-hour blood pressure and <120/70
mm Hg for night-time blood pressure.2
A recent Clinical Inquiry summarized 
3 cohort trials—2 showed white-coat
hypertension patients had lower risk of
cardiovascular events and 1 showed no
difference between patients with white-
coat hypertension and patients with sus-
tained hypertension.3 Identifying patients
with white-coat hypertension is important
to avoid overtreating individuals at lower
risk of cardiovascular events.
Which patients with elevated blood
pressure on repeated visits have white-coat
hypertension? In studies of patients, most
of whom have Stage I hypertension
(140–159/90–99 mm Hg), anywhere from
10% to 50% have white-coat hyper-
Michael Fisher, MD, MPH, Jean Blackwell, MLS
University of North Carolina-Chapel Hill
CLINICAL INQUIRIES
C O N T I N U E D
Women, older
patients, and
those with lower
and fewer office
blood pressure
measurements
were more likely
to have white-coat
hypertension
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tension (TABLE). In a joint multivariate
analysis of 2 cohort studies, which
enrolled 1564 subjects with uncomplicat-
ed stage I hypertension, white-coat
hypertension was associated with lower
office systolic blood pressure, female
gender, and nonsmoking.2 Similarly, a
large international database of 2492 sub-
jects found that women, older subjects,
and those with lower and fewer  office
systolic blood pressure measurements
were more likely to have white-coat
hypertension.4 In another analysis of
1333 Italian subjects, the prevalence of
white-coat hypertension was 33.3% in
those with stage I hypertension, 11%
with stage II, and 3 % with stage III.5 A
study of more than 600 men over 20
T A B L E
ATTRIBUTE SUBJECTS COMPARISON P VALUE
Gender, % with WCH 5716* 17% of females <.001
14% of males
% female WCH v SH group 1564† 45% v 33% .002
Ratio female: male with WCH 2634§ Odds ratio=1.92 
(95% CI, 1.45–2.54) <.001
Mean age, WCH vs SH 1564† 40 vs 39 years .52
% with WCH in 4 age groups 5716* <35 y=12%, <.001
35–50 y=14%, 
50–65 y=16%, 
>65 y=17%
Currently smoking, % with WCH 5716* No=16.7%, Yes=11.3% <.001
Currently smoking  % WCH v SH 1564† 7% v 24% .04
BMI, % WCH in 3 groups 5716* < 25=16% NS
25–30=15%
>30=15%
BMI, WCH group vs SH group 1564† 25.4 vs 25.9 NS
414‡ 23.9 vs 24.7 <.05
Original clinic SBP, % with WCH 5716* 140–159=31.2% <.001
160–170=18.7% 
171–180=11.8%   
2492§ 140–150=65% .004
151–160=53%
161–170=33%
LV Mass (g), WCH v SH 1564† 160 vs 180 .001
LV Mass Index (g/m2) WCH v SH 414‡ 126 vs 136 <.01
WCH, white coat hypertension; SBP, systolic blood pressure; SH, sustained hypertension; 
CI, confidence interval; BMI, body-mass index; NS, not significant; LV, left ventricular.
*Patients referred to a blood pressure unit over 22-year period.7
† A combination of 2 studies of clinic patients with stage I hypertension (140–159/90–99 mm Hg).2
‡ 50-year-old men in a community in Finland invited to a health survey with a 20-year follow-up.6
§ Data from 24 pooled studies of ambulatory blood pressure monitoring.4
Patient attributes and white-coat hypertension
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If home blood
pressure returns
to normal in those
with office 
hypertension, 
two thirds will
still have 
sustained 
hypertension
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years in Finland compared those who
developed white-coat hypertension and
those with sustained hypertension. The
hypertensive patients had more microal-
buminuria, a greater left ventricular mass
on echo, increased cholesterol esters, and
a greater body-mass index (all P≤.05)
than patients with white-coat hyperten-
sion.  Smoking status was similar in both
groups, in contrast to other studies.6 A
recent study did not find body-mass
index distinguished white-coat hyperten-
sion from sustained hypertension.7
Using home blood pressure as a
screening tool is a problem because of the
low sensitivity and poor PV+. In the
THOP study (247 subjects), which used
ambulatory blood pressure monitoring as
the reference method, home blood pres-
sure had a high specificity (89%) and
high negative predictive value (PV–)
(97%) but a lower sensitivity (68%) and
low PPV (33%).8 In other words, if
home blood pressure shows hyperten-
sion, there is a 97% chance the patient
has sustained hypertension, but if home
blood pressure returns to normal in
patients with office hypertension, two
thirds of patients will still have sustained
hypertension. In another study that
enrolled patients from a hypertension
clinic, 133 untreated patients with dias-
tolic blood pressure 90 to 115 mm Hg
underwent ambulatory blood pressure
monitoring for a reference standard. The
sensitivity of home blood pressure moni-
toring in identifying white-coat hyperten-
sion was 61% and the PV+ was 48%.9
Recommendations from others
The European Society of Hypertension
Working Group on Blood Pressure
Monitoring recommends that subjects
with blood pressure 140–159/90–99 mm
Hg at several visits should have ambula-
tory blood pressure monitoring because
33% of those people will have white-coat
hypertension. Women, nonsmokers,
those with recent hypertension, a limited
number of blood pressure determinations
and small left ventricular mass on echo
should also have ambulatory blood pres-
sure monitoring. There should be a
search for metabolic risk factors and tar-
get organ damage. Those patients aware
that their blood pressures are lower out-
side the office should be considered for
ambulatory blood pressure monitoring.10
The latest Joint National Committee
report (JNC VII) indicates that ambula-
tory blood pressure monitoring may be
useful to detect white-coat hypertension
among patients with hypertension and
no target organ damage, and those with
episodic hypertension.11
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